Does route of administration affect the outcome of TNF antagonist therapy? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2004-06-21

AUTHORS

Sergio Schwartzman, G James Morgan

ABSTRACT

The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy. More... »

PAGES

s19-s23

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/ar996

DOI

http://dx.doi.org/10.1186/ar996

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013531351

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15228617


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Rheumatoid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Routes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Necrosis Factor-alpha", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hospital for Special Surgery, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.239915.5", 
          "name": [
            "Hospital for Special Surgery, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartzman", 
        "givenName": "Sergio", 
        "id": "sg:person.014133305773.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA", 
          "id": "http://www.grid.ac/institutes/grid.413480.a", 
          "name": [
            "Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morgan", 
        "givenName": "G James", 
        "id": "sg:person.016267004752.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267004752.30"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2004-06-21", 
    "datePublishedReg": "2004-06-21", 
    "description": "The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/ar996", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "Suppl 2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "route of administration", 
      "tumor necrosis factor antagonists", 
      "anti-TNF therapy", 
      "dose of etanercept", 
      "TNF antagonist therapy", 
      "necrosis factor antagonists", 
      "biologic response modifiers", 
      "choice of therapy", 
      "oral methotrexate", 
      "medication regimen", 
      "antagonist therapy", 
      "rheumatoid arthritis", 
      "medication adherence", 
      "weeks 0", 
      "patients' attitudes", 
      "patient outcomes", 
      "factor antagonists", 
      "response modifiers", 
      "US Food", 
      "Drug Administration", 
      "healthcare team", 
      "etanercept", 
      "adalimumab", 
      "therapy", 
      "administration", 
      "weeks", 
      "infliximab", 
      "regimen", 
      "methotrexate", 
      "dose", 
      "outcomes", 
      "arthritis", 
      "patients", 
      "antagonist", 
      "doses", 
      "disease", 
      "adherence", 
      "FDA", 
      "dosage", 
      "important factor", 
      "management", 
      "food", 
      "factors", 
      "benefits", 
      "team", 
      "attitudes", 
      "route", 
      "combination", 
      "modifiers", 
      "members", 
      "choice", 
      "USA", 
      "interaction", 
      "Europe", 
      "class"
    ], 
    "name": "Does route of administration affect the outcome of TNF antagonist therapy?", 
    "pagination": "s19-s23", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013531351"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/ar996"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15228617"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/ar996", 
      "https://app.dimensions.ai/details/publication/pub.1013531351"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_394.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/ar996"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/ar996'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/ar996'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/ar996'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/ar996'


 

This table displays all metadata directly associated to this object as RDF triples.

151 TRIPLES      21 PREDICATES      87 URIs      79 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/ar996 schema:about N3c1a9d87dcee4d81b073aeb5d80eb2f1
2 N7046a0d3ea284fee9da01ca860a6f3dc
3 N70ee6ad86de14585a25899e38b619731
4 N72a540baf7ea46f4b1d4541f398972af
5 Nd88669d4b21d4686a484c3d98423d91a
6 Nd8e95717cf6741e5801d4e3b88ebc363
7 anzsrc-for:11
8 anzsrc-for:1115
9 schema:author Nca87a6e1bf03482a93763c3fc1966f10
10 schema:datePublished 2004-06-21
11 schema:datePublishedReg 2004-06-21
12 schema:description The tumor necrosis factor (TNF) antagonists are parenterally administered biologic response modifiers indicated for the management of rheumatoid arthritis. Although infliximab, etanercept, and adalimumab are all members of this class, they differ in route of administration and dosing regimen. In the USA and in Europe, infliximab, in combination with oral methotrexate, is administered intravenously, initially at a dose of 3 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter. The US Food and Drug Administration (FDA) has further approved that the dosage can be increased to 10 mg/kg and the doses can be given as often as every 4 weeks to optimize patient outcome (information based on the US package insert dated June 2002). Etanercept and adalimumab are given subcutaneously and can be self-injected. The FDA-approved dose of etanercept is 25 mg twice weekly, and of adalimumab is 40 mg every 2 weeks with methotrexate, or 40 mg alone. Medication adherence, possibly the most important factor in maintaining the benefits of anti-TNF therapy, is influenced by the interaction between the patient and his or her healthcare team, the patient's attitude toward the disease and medication regimen, and the choice of therapy.
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf N28cb96b73e8442ba8bf2ee2568a78516
17 Nddd7910d78564610891512b5925bbb2f
18 sg:journal.1297499
19 schema:keywords Drug Administration
20 Europe
21 FDA
22 TNF antagonist therapy
23 US Food
24 USA
25 adalimumab
26 adherence
27 administration
28 antagonist
29 antagonist therapy
30 anti-TNF therapy
31 arthritis
32 attitudes
33 benefits
34 biologic response modifiers
35 choice
36 choice of therapy
37 class
38 combination
39 disease
40 dosage
41 dose
42 dose of etanercept
43 doses
44 etanercept
45 factor antagonists
46 factors
47 food
48 healthcare team
49 important factor
50 infliximab
51 interaction
52 management
53 medication adherence
54 medication regimen
55 members
56 methotrexate
57 modifiers
58 necrosis factor antagonists
59 oral methotrexate
60 outcomes
61 patient outcomes
62 patients
63 patients' attitudes
64 regimen
65 response modifiers
66 rheumatoid arthritis
67 route
68 route of administration
69 team
70 therapy
71 tumor necrosis factor antagonists
72 weeks
73 weeks 0
74 schema:name Does route of administration affect the outcome of TNF antagonist therapy?
75 schema:pagination s19-s23
76 schema:productId N290834af6f484561ac70a8f76380bda6
77 Na2db1ac142274b419fea36594a106a54
78 Nc4efe23538874b89a9bacd9b394def88
79 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013531351
80 https://doi.org/10.1186/ar996
81 schema:sdDatePublished 2021-12-01T19:15
82 schema:sdLicense https://scigraph.springernature.com/explorer/license/
83 schema:sdPublisher Nce2a532de428433a98ea76bc78b1ab93
84 schema:url https://doi.org/10.1186/ar996
85 sgo:license sg:explorer/license/
86 sgo:sdDataset articles
87 rdf:type schema:ScholarlyArticle
88 N28cb96b73e8442ba8bf2ee2568a78516 schema:issueNumber Suppl 2
89 rdf:type schema:PublicationIssue
90 N290834af6f484561ac70a8f76380bda6 schema:name pubmed_id
91 schema:value 15228617
92 rdf:type schema:PropertyValue
93 N3c1a9d87dcee4d81b073aeb5d80eb2f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Arthritis, Rheumatoid
95 rdf:type schema:DefinedTerm
96 N7046a0d3ea284fee9da01ca860a6f3dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Humans
98 rdf:type schema:DefinedTerm
99 N70ee6ad86de14585a25899e38b619731 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Tumor Necrosis Factor-alpha
101 rdf:type schema:DefinedTerm
102 N72963f03526b4e2fbe894d6f8769190d rdf:first sg:person.016267004752.30
103 rdf:rest rdf:nil
104 N72a540baf7ea46f4b1d4541f398972af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Antirheumatic Agents
106 rdf:type schema:DefinedTerm
107 Na2db1ac142274b419fea36594a106a54 schema:name doi
108 schema:value 10.1186/ar996
109 rdf:type schema:PropertyValue
110 Nc4efe23538874b89a9bacd9b394def88 schema:name dimensions_id
111 schema:value pub.1013531351
112 rdf:type schema:PropertyValue
113 Nca87a6e1bf03482a93763c3fc1966f10 rdf:first sg:person.014133305773.18
114 rdf:rest N72963f03526b4e2fbe894d6f8769190d
115 Nce2a532de428433a98ea76bc78b1ab93 schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 Nd88669d4b21d4686a484c3d98423d91a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Drug Administration Routes
119 rdf:type schema:DefinedTerm
120 Nd8e95717cf6741e5801d4e3b88ebc363 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Treatment Outcome
122 rdf:type schema:DefinedTerm
123 Nddd7910d78564610891512b5925bbb2f schema:volumeNumber 6
124 rdf:type schema:PublicationVolume
125 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
126 schema:name Medical and Health Sciences
127 rdf:type schema:DefinedTerm
128 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
129 schema:name Pharmacology and Pharmaceutical Sciences
130 rdf:type schema:DefinedTerm
131 sg:journal.1297499 schema:issn 1478-6354
132 1478-6362
133 schema:name Arthritis Research & Therapy
134 schema:publisher Springer Nature
135 rdf:type schema:Periodical
136 sg:person.014133305773.18 schema:affiliation grid-institutes:grid.239915.5
137 schema:familyName Schwartzman
138 schema:givenName Sergio
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014133305773.18
140 rdf:type schema:Person
141 sg:person.016267004752.30 schema:affiliation grid-institutes:grid.413480.a
142 schema:familyName Morgan
143 schema:givenName G James
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016267004752.30
145 rdf:type schema:Person
146 grid-institutes:grid.239915.5 schema:alternateName Hospital for Special Surgery, New York, NY, USA
147 schema:name Hospital for Special Surgery, New York, NY, USA
148 rdf:type schema:Organization
149 grid-institutes:grid.413480.a schema:alternateName Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
150 schema:name Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
151 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...